There are several reports in the literature concerning urinary 17-ketosteroids in patients with Cushing's syndrome associated with bilateral adrenal cortical hyperplasia (1) (2) (3) (4) (5) (6) (7) . In most of the published studies, identification of the individual 17-ketosteroids was incomplete, so that the sum of detailed information available is limited. With the development of improved techniques for steroid fractionation and identification, a re-evaluation of the problem seemed indicated. The present investigation was therefore undertaken with a twofold purpose: 1) to make a detailed study of the urinary 17-ketosteroids in patients with this form of Cushing's syndrome; and 2) to determine whether or not the administration of corticotropin to normal subjects was capable of reproducing the excretory pattern of 17-ketosteroids found in Cushing's syndrome with bilateral adrenal cortical hyperplasia. It seemed likely that the data resulting from such studies might provide useful information bearing upon the pathogenesis of this disorder.
MATERIALS AND METHODS
Patients with Cushing's syndrome and bilateral adrenal cortical hyperplasia. Seven patients having the typical clinical and laboratory features of Cushing's syndrome served as the subjects for the study. Pertinent data obtained from these patients are presented in Table I . The absence of adrenal cortical tumor was proved in six of the seven patients by operation (bilateral total or subtotal adrenalectomy). In the seventh patient (Bon.), intravenous pyelography and retroperitoneal insufflation of air gave no evidence of a suprarenal mass. Two of the subjects (Bon. and Fan.) were studied before and during the administration of corticotropin. Bon. received a single intravenous infusion of lyophilized adrenocorticotropic hormone (ACTH), 25 Subjects uwthout adrenal cortical disease. Normal values for the individual 17-ketosteroids were derived from a study of 8 normal males (age range, 21 to 35) and 13 normal females (age range, 20 to 31). These subjects were presumably healthy laboratory workers who were carrying on their usual activities. The average values are summarized in Table II . The data are to be published in detail elsewhere.
Two normal females aged 26 and 27 years were studied before and during three day periods of corticotropin administration (ACTH gel, 40 I.U. intramuscularly, twice a day). In addition, studies were carried out in two patients who had been treated with corticotropin for prolonged periods. Patient M.S., a 41 year old white female with bronchial asthma, had received intramuscular doses of 5 to 20 I.U. (lyophilized and gel preparations) with a frequency ranging from once a day to once a week for three years. Patient E.U., a 58 year old white male with rheumatoid arthritis, had been given intramuscular corticotropin (lyophilized and gel) in doses of 2 to 20 I.U. daily or every other day for two years.
Methods. Twenty-four hour urine specimens were collected for periods of one to seven days. If not proc- W E essed immediately, the specimens were refrigerated without preservative. Total urinary 17-ketosteroids (per 24 hours) were estimated by the colorimetric method of Holtorff and Koch (8) . For the isolation of the individual 17-ketosteroids, the urine was subjected to enzymatic hydrolysis (betaglucuronidase). This was followed by cold, then hot, acid hydrolysis (9) . Extracts were chromatographed on alumina according to the technique of Lakshmanan and Lieberman (10) . All Zimmermann values were corrected for differences in chromogenicity of the various steroids (11) . In every instance, steroids in the chromatographic peaks were identified by infrared spectroscopy.
With this method of fractionation (10) it is not possible to separate chromatographically dehydroisoandrosterone from isoandrosterone, androsterone from A9-androstenolone, or etiocholanolone from A9-etiocholenolone.1 Quantitation of the individual components of these three binary mixtures was performed by the sulfuric acid chromogen method of Bitman, Rosselet, Reddy and Lieberman (12) . Since the A9-unsaturated compounds are probably artifacts of dehydration resulting from hot acid hydrolysis of the 11 beta-hydroxy 17-ketosteroids (13), the quantities of A9-androstenolone and A-etiocholenolone were added to the values for 11 beta-hydroxyandrosterone and to 11 beta-hydroxyetiocholanolone, respectively. The presence of the A' steroids and of isoandrosterone was established in each instance by infrared spectroscopy, as well as by the sulfuric acid chromogen method (12) . RESULTS 
1.
Cushing's syndrome with bilateral adrenal cortical hyperplasia Values for the individual 17-ketosteroids in the seven patients with bilateral adrenal cortical hy- 1 The following trivial names for C19 steroids are used in this paper: androsterone for 3a-hydroxyandrostan-17-one; etiocholanolone for 3a-hydroxyetiocholan-17-one; dehydroisoandrosterone for 3p-hydroxy-A5-androsten-17-one; isoandrosterone for 3,f-hydroxyandrostan-17-one; A9-androstenolone for 3a-hydroxy-A" '-androsten-17-one; A-etiocholenolone for 3a-hydroxy-A9' u-etiocholen-17-one; llp-hydroxyetiocholanolone for 3a,118-dihydroxyetiocholan-17-one; llr-hydroxyandrosterone for 3a,11p-dihydroxyandrostan-17-one; 11-ketoetiocholanolone for 3a-hydroxyetiocholane-11,17-dione; and 11-ketoandrosterone for 3a-hydroxyandrostane-11,17-dione. For certain C21 steroids, the following trivial names are employed: hydrocortisone for 11,8,17a,21-trihydroxy-A'-pregnene-3,20-dione; Substance S for 17a,21-dihydroxy-A'-pregnene-3,20-dione; tetrahydro E for 3a,17a,21-trihydroxypregnane-11,20-dione; tetrahydro F for 3a,11f,17a,21-tetrahydroxypregnan-20-one; tetrahydro S for 3a,17a,21-trihydroxypregnan-20-one; 17a-hydroxyprogesterone for 17a-hydroxy-A'-pregnene-3,20-dione; 17a-hydroxypregnanolone for 3a,17a-dihydroxypregnan-20-one; and pregnanetriol for pregnane-3a,17a,20a-triol. perplasia are shown in Table III . The total quantity of identified 17-ketosteroids was moderately increased in three subjects (Arp., See., Gol.), markedly increased in one (Fan.), and normal in the remaining three (Cor., Par. and Bon.).
Analysis of urinary 17-ketosteroids revealed three findings of note. 1) When compared with the normal subjects (Table II) , all seven patients with Cushing's syndrome were observed to excrete excessive amounts of 11-oxygenated 17-ketosteroids. The proportion of 11-oxygenated 17-ketosteroids relative to total ketosteroids was also greater than normal. 11 Beta-hydroxyandrosterone, 11 beta-hydroxyetiocholanolone, and 11-ketoetiocholanolone together comprised 40 to 66 per cent of the total as compared with 9 to 40 per cent in the normal individuals (Tables II and  III) . Of special interest was the relatively large amount of 11 beta-hydroxyandrosterone identified in the urine of five of the seven patients (all except Arp. and Par., Table III ) (see Discussion).
2) In six of the seven patients (all except Fan.), the total quantity of 11-deoxy 17-ketosteroids was within normal limits (compare data of Tables II  and III) . A striking finding in five of the seven (all except Cor. and Bon.) was the alteration in the ratio of etiocholanolone to androsterone. In the normal subject, the ratio of the two steroids averages about 1 (Table II) . The average etiocholanolone to androsterone ratio in these patients with Cushing's syndrome was 4.1 (Table III). 3) In only two of the seven patients with Cushing's syndrome was there a detectable quantity of the beta ketosteroids, isoandrosterone and dehydroisoandrosterone (Patients See. and Fan., Table  III ). Neither of these two subjects excreted an excessive proportion of beta ketosteroids, but Fan. showed a marked increase in the absolute quantity of dehydroisoandrosterone (14.0 mg. per 24 hours as compared with 6.4 mg. per 24 hours, the extreme upper limit observed in the normal females).
Effects of corticotropin administration. and Gallagher for normal subjects to whom ACTH was administered (14, 15 Table II , normal subjects). The quantity of the individual 11-oxygenated 17-ketosteroids could not be exactly determined since 11 beta-hydroxyandrosterone was not chromatographically separated from 11 -ketoetiocholanolone. DISCUSSION The urinary 17-ketosteroid pattern observed in these patients with Cushing's syndrome and bilateral adrenal cortical hyperplasia is a characteristic one, and differs from the ketosteroid pattern found in normal subjects and from that reported in other types of adrenal cortical disease (16, 30, 32) . But the abnormal 17-ketosteroid pattern in Cushing's syndrome with adrenal hyperplasia derives its chief interest from its possible bearing upon the problem of deranged adrenal cortical secretion, and further, from its possible bearing upon the pathogenesis of the disorder. In the following discussion, it is assumed that the urinary steroid pattern is a more or less direct reflection of adrenal cortical secretion. The possibility cannot be excluded that some or all of the abnormalities observed might have been related to changes in the peripheral metabolism of adrenal steroids, changes which are peculiar to Cushing's syndrome. To date, no such metabolic errors in Cushing's syndrome have been demonstrated.
The increase in the urinary excretion of 11-oxygenated 17-ketosteroids is not surprising and can be adequately accounted for by the increased amount of hydrocortisone which is presumably secreted by the adrenal cortex in Cushing's syndrome. The increase in hydrocortisone secretion appears to be amply documented by the findings of elevated plasma hydrocortisone levels (17) (18) (19) and increased urinary excretion of C21 metabolic products of hydrocortisone, tetrahydro E and tetrahydro F (20) . 11 Beta-hydroxyandrosterone, 11 beta-hydroxyetiocholanolone, and 11-ketoetiocholanolone have been shown to be the principal C19 excretory products of administered hydrocortisone 2 (22) . The relative proportions of the individual 11-oxy 17-ketosteroids one to another are not readily accounted for by an increased secretion of hydrocortisone alone. The infusion of 4-C14-labeled hydrocortisone in man has been reported to result in the urinary excretion of labeled 11 beta-hydroxyandrosterone, 11 beta-hydroxyetiocholanolone, and 1 1-ketoetiocholanolone in the ratio 2: 9: 9 (21). The ratio of the three steroids observed in certain of the patients with Cushing's syndrome is very different from this (Table III , Patients Cor., See., Bon. and Gol., in whom these ratios were approximately 8: 2: 1, 13: 1: 1, 7: 1: 3 and 5: 4: 2). It is possible that a precursor other than hydrocortisone may contribute in an important way to the excretion of 11-oxygenated 17-ketosteroids in Cushing's syndrome. One such precursor might conceivably be A4-androstene-1 1 beta-ol-3,17-dione, a normal constituent of adrenal vein blood, which has been shown to be converted to 11 betahydroxyandrosterone, 11 beta-hydroxyetiocholanolone, and 1 1-ketoetiocholanolone in the ratio 12:1:2 (23).
The ratio of etiocholanolone to androsterone in five of the seven patients with Cushing's syndrome is above the extreme upper limit found in normal individuals in the present investigation (compare Tables II and III ) and in earlier studies by Kappas, Dobriner and Gallagher3 (14, 15) . The average ratio of etiocholanolone to androsterone in normal subjects is close to unity (Table II) (14, 15) . The identity of the adrenal cortical precursor of etiocholanolone and androsterone in normal subjects is not known, but the 1: 1 urinary ratio of the two steroids has led to speculation concerning 2 Gallagher was unable to show that hydrocortisone administration gives rise to an appreciable quantity of urinary 11-keto-androsterone (21) . In the present study, it was also impossible to identify this steroid conclusively in any patient. With the methods used, trace amounts (less than 100 ,tg. per 24 hours) could have gone undetected. 8 The high average ratio of etiocholanolone (24) . their origin. For example, it has been postulated (14, 15, (25) (26) (27) ) that the precursor is a C19 11-deoxy steroid because, in a limited number of studies, it has been shown that the administration of certain of these steroids (testosterone, dehydroisoandrosterone, A4-androstene-3,17-dione) results in the urinary excretion of etiocholanolone and androsterone in roughly equal proportions [etiocholanolone: androsterone 1.5: 1 (26), average etiocholanolone: androsterone ratio in several experiments 1.7: 1 (27)]. Thus, although a C19 precursor may contribute to the quantity of etiocholanolone in the patients with Cushing's syndrome, a major portion of this steroid may well be derived from a C21 precursor. One precursor which might be supposed to account for the altered ratio of etiocholanolone to androsterone is the C21 1 1-deoxy 17-hydroxysteroid, Reichstein's Substance S. Administration of this steroid to human subjects has been found to result in the urinary excretion of greater quantities of etiocholanolone than of androsterone (28, 29 ). Another 1 1-deoxy 17-hydroxy steroid of the C21 series, 17 alpha-hydroxyprogesterone, administration of which has been shown to give rise to a high etiocholanolone: androsterone ratio, does not appear to be a likely precursor because its principal excretory products, pregnanetriol and 17 alpha-hydroxypregnanolone, are not increased in this form of Cushing's syndrome (30) . In a few of these patients, pregnanetriol was found in amounts not exceeding normal. In any event, it would seem that a search for the 1 1-deoxy 17-ketosteroid precursors in this disorder should be directed toward C21 rather than C19 compounds (27) .
Dehydroisoandrosterone was not isolated in excess from any patient with Cushing's syndrome except Fan. (Table III) . This observation is in accord with the results of most studies of urinary 17-ketosteroids in Cushing's syndrome (31) . It has been found by most investigators that excessive quantities of dehydroisoandrosterone are not present in the urine of patients with adrenal hyperplasia, but that large amounts of this steroid may be present in the urine of patients with adrenal cortical carcinoma (31) . Recent studies suggest that abnormally large quantities of dehydroisoandrosterone are by no means invariably found in adrenal cortical carcinoma (32) . Be-cause the precursor (or precursors) of dehydroisoandrosterone is unknown at this time, the true significance of this steroid as a urinary excretory product is difficult to assess (33, 34) .
Since all of the clinical features of Cushing's syndrome can be reproduced by the administration of ACTH, it was considered important to determine whether or not this pituitary hormone was capable of bringing about the changes in urinary 17-ketosteroid excretion which appeared to be characteristic of the naturally-occurring disorder. The present studies are in agreement with previous work in that they show a greater relative rise in 11-oxy than in 11-deoxy 17-ketosteroid excretion after the short-term administration of ACTH (15) . The failure to bring about an increase in the ratio of etiocholanolone to androsterone with a short course of ACTH is also in agreement with earlier work (14, 15 ). In contrast, the administration of corticotropin to two patients for two and three years was associated with an increase in this ratio, which, in Patient E.U. (Table VI) , was quantitatively comparable to the change in etiocholanolone: androsterone ratio observed in the patients with adrenal cortical hyperplasia (Table III) . On the basis of the limited evidence now available, it seems improbable that chronic disease alone (e.g., rheumatoid arthritis as in E.U.) satisfactorily accounts for the abnormality in 1 1-deoxy 17-ketosteroid excretion. Birke has reported that the ratio of etiocholanolone to androsterone in a group of patients with long-standing rheumatoid arthritis was essentially normal (35) .
Concerning possible alterations in 17-ketosteroid precursors secreted by the ACTH-stimulated adrenal cortex, the observations of Touchstone, Bulaschenko, Richardson and Dohan may be pertinent (20) . These workers have reported the isolation of a metabolic product of Substance S, tetrahydro S, from the urine of ACTH-treated subjects. Although corticotropin-treated normals and patients with Cushing's syndrome associated with bilateral adrenal hyperplasia have high etiocholanolone: androsterone ratios (present study), one hesitates to draw an analogy between the two groups. This is because tetrahydro S has to date been definitely identified only in the urine of patients with Cushing's syndrome associated with adrenal cortical carcinoma (20, 36) , and only tentatively identified in urine of patients with adrenal hyperplasia (20) . It is also necessary to exercise caution in equating bilateral adrenal cortical hyperplasia with ACTH-treated normal subjects, since several investigators have failed to demonstrate increased quantities of circulating ACTH in patients with Cushing's syndrome (37, 38) , although abnormal corticotropic activity of unknown origin has been reported (39).
It is conceivable that administered ACTH,
given over long periods, may be capable of causing profound qualitative changes in corticosteroid biosynthesis, perhaps by affecting the relative activities of the various steroid hydroxylases in the adrenal cortex [e.g., 11 beta-hydroxylase (40)].
An example of such a change may perhaps be found in the observation of Kass, Hechter, Macchi and Mou that prolonged ACTH administration altered the ratio of hydrocortisone to corticosterone in the adrenal vein blood of rabbits (41) . A possible relationship between the corticotropin-stimulated adrenal cortex and naturally-occurring adrenal cortical hyperplasia remains a subject for future investigation.
SUMMARY
In Cushing's syndrome associated with bilateral adrenal cortical hyperplasia, urinary 17-ketosteroids were fractionated by means of column chromatography and identified by infrared spectroscopy. The excretory pattern of 17-ketosteroids in seven patients with this disorder exhibited the following characteristics:
1. An absolute and relative increase in the 11-oxygenated 17-ketosteroids.
2. An absolute increase in the quantity of 11 beta-OH-androsterone which was out of proportion to the value that would be expected on the basis of excessive adrenal secretion of hydrocortisone alone.
3. An average ratio of etiocholanolone to androsterone approximately four times greater than that observed in normal subjects. Total values of androsterone were normal in all seven; total values of etiocholanolone were above the upper limit of normal in four.
4. The absence of detectable quantities of dehydroisoandrosterone in five of the seven patients; the presence of an abnormally large quantity of dehydroisoandrosterone in one of the seven.
Prolonged administration of corticotropin to two patients without adrenal cortical disease was associated with a high ratio of etiocholanolone to androsterone.
